InvestorsHub Logo
Followers 275
Posts 32727
Boards Moderated 0
Alias Born 11/14/2013

Re: None

Tuesday, 05/21/2019 6:50:36 AM

Tuesday, May 21, 2019 6:50:36 AM

Post# of 704148
Blackrock is Tocagen's number one institutional shareholder.

Blackrock's connection to Cognate seems less coincidental to me now.

Just saying. Their overall view on healthcare is it's too expensive and translation from clinic to bedside too slow.

When asked in March 2019 why they should spend more alpha on the upcoming IA (over a month off from today) Tocagen management replied they felt it was worth the risk so that they could move move it toward commercialization (get it to patients) sooner if possible.

Toca's phase III trial was never blinded.

Respect Risk. Conduct Your Own Due Diligence. Manage your assets wisely. Diversify.

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent NWBO News